The Experts below are selected from a list of 57 Experts worldwide ranked by ideXlab platform

Heiwa Kanamori - One of the best experts on this subject based on the ideXlab platform.

  • A New Three-Way Translocation t(4;11;7)(q21;q23;q22) in a Mixed-Phenotype Acute Leukemia
    Hindawi Limited, 2011
    Co-Authors: Hirotaka Takasaki, Takayoshi Tachibana, Masatsugu Tanaka, Atsuo Maruta, Yoshiaki Ishigatsubo, Heiwa Kanamori
    Abstract:

    A 68-year-old man was admitted to our hospital in September 2008 because of a left-sided chest pain. Bone marrow examination showed that 85.5% of leukemic cells were positive for myeloperoxidase (MPO) and were negative for esterase stain. Flow cytometric analysis (FCM) revealed the expression of CD19, CD79a, CD13, CD33, CD34, and HLA-DR on the blasts. Cytogenetic analysis of bone marrow cells using the G-banding technique demonstrated 47, XY, +X, t(4;11;7)(q21;q23;q22) in five of the 20 analyzed cells. The patient was diagnosed as having mixed biphenotypic acute Leukemia according to the European Group for Immunologic Classification of Leukemia criteria. Mixed-phenotype acute Leukemia is a rare, difficult to diagnose entity. Whether patients with mixed-phenotype acute Leukemia should be treated with regimens designed for acute myeloid Leukemia, acute lymphoblastic Leukemia, or both remains unclear

  • A New Three-Way Translocation t(4;11;7)(q21;q23;q22) in a Mixed-Phenotype Acute Leukemia
    2011
    Co-Authors: Yoshiaki Ishigatsubo, Heiwa Kanamori
    Abstract:

    Copyright © 2011 Hirotaka Takasaki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. A 68-year-old man was admitted to our hospital in September 2008 because of a left-sided chest pain. Bone marrow examination showed that 85.5 % of leukemic cells were positive formyeloperoxidase (MPO) and were negative for esterase stain. Flow cytometric analysis (FCM) revealed the expression of CD19, CD79a, CD13, CD33, CD34, and HLA-DR on the blasts. Cytogenetic analysis of bone marrow cells using the G-banding technique demonstrated 47, XY, +X, t(4;11;7)(q21;q23;q22) in five of the 20 analyzed cells. The patient was diagnosed as having mixed biphenotypic acute Leukemia according to the European Group for Immunologic Classification of Leukemia criteria. Mixed-phenotype acute Leukemia is a rare, difficult to diagnose entity. Whether patients with mixed-phenotype acute Leukemia should be treated with regimens designed for acute myeloid Leukemia, acute lymphoblastic Leukemia, or both remains unclear. 1

Mirta Mikulic - One of the best experts on this subject based on the ideXlab platform.

  • biological features and outcome of biphenotypic acute Leukemia a case series
    Hematology Oncology and Stem Cell Therapy, 2008
    Co-Authors: Mirta Mikulic, Drago Batinic, Mirna Sucic, Sanja Davidovicmrsic, Klara Dubravcic, Damir Nemet, Ranka Serventiseiwerth, Dubravka Sertic, Boris Labar
    Abstract:

    BACKGROUND Biphenotypic acute Leukemia (BAL) is a distinct entity that is immunophenotypically defined by the European Group for the Immunological Classification of Leukemia (EGIL) scoring system and accounts for less than 5% of all acute Leukemia cases. Since it is a rare and heterogeneous form of acute Leukemia with an allegedly poor outcome, there is no consensus on the best treatment approach in these patients. Our objective was to analyze the biological features and outcome of patients diagnosed with BAL in our institution. PATIENTS AND METHODS Using the EGIL system, we identified 21 cases (3.9%) of BAL from 535 newly diagnosed acute Leukemia patients in an 11-year period. RESULTS There were ten cases of myeloid + B-lymphoid Leukemia, eight cases of myeloid + T-lymphoid, one case of B + T-lymphoid and two cases of trilineage (myeloid + B + T-lymphoid Leukemia). The complete remission (CR) rate with high-dose chemotherapy was 72% and overall survival at 5 years was 21%. Patients that received acute lymphoblastic Leukemia-oriented chemotherapy had a higher CR rate compared with those who received acute myeloid Leukemia-oriented chemotherapy (100% vs. 60%, P = .007). The white blood cell count at diagnosis was found to have statistically significant impact on survival. CONCLUSION Despite the progress in the treatment of acute Leukemia, the prognosis of BAL remains poor and treatment protocols devised explicitly for this entity should be investigated in prospective collaborative studies.

  • p015 outcome in a small series of biphenotypic acute Leukemia bal patients
    Leukemia Research, 2007
    Co-Authors: Mirta Mikulic, Drago Batinic, Klara Dubravcic, Damir Nemet, Ranka Serventiseiwerth, Dubravka Sertic, L Rnjak, Mirando Mrsic, Mirna Golemovic, Sanja Mrsic
    Abstract:

    Background: Less than 5% of all cases of acute Leukemia are classified as biphenotypic acute Leukemia (BAL). Being a distinct entity recognized by the WHO Classification, BAL is immunophenotypically defined by the European Group for the Immunological Classification of Leukemia (EGIL) scoring system, whereas according to FAB Classification BAL may present as one of the ALL or AML subtypes. Since BAL is both a rare form of acute Leukemia and shows diverse biological features, there is no consensus on the best treatment approach in these patients. Aim: Our aim was to analyze the laboratory characteristics and the outcome of patients diagnosed with BAL. Patients and methods: Using the EGIL system, we identified 21 cases (4%) of BAL from 535 newly diagnosed acute Leukemia patients in the Zagreb Clinical Hospital Center in the period from end 1994-2006. Results: There were 16 male and 5 female patients with median age of 44 years (16- 74). Among them, there were 12 cases of B+myeloid Leukemia (55%), 8 cases of T+myeloid (36%), 1 case of B+T lymphoid (5%) and 1 case of trilineage B+T+myeloid Leukemia (5%). Morphologic assessment showed myeloid features in 9, lymphoid features in 6 and undifferentiated in 6 patients. Cytogenetic findings revealed normal as well as a wide range of aberrant karyotypes. The patients were treated according to the protocols for AML or ALL or with low-dose chemotherapy - 8, 10 and 3 patients, respectively. In the majority of patients overall survival was poor with a median of 7 months (1- 100) and with a probability of survival at two years of 35%. Conclusion: Despite the progress in the treatment of acute Leukemia, the definition and the prognosis of BAL remains poor. Current treatment approach is heterogeneous and still based on cytomorphology. Treatment protocols designed specifically for this type of Leukemia should be devised and studied in larger groups of patients.

Ranka Serventiseiwerth - One of the best experts on this subject based on the ideXlab platform.

  • biological features and outcome of biphenotypic acute Leukemia a case series
    Hematology Oncology and Stem Cell Therapy, 2008
    Co-Authors: Mirta Mikulic, Drago Batinic, Mirna Sucic, Sanja Davidovicmrsic, Klara Dubravcic, Damir Nemet, Ranka Serventiseiwerth, Dubravka Sertic, Boris Labar
    Abstract:

    BACKGROUND Biphenotypic acute Leukemia (BAL) is a distinct entity that is immunophenotypically defined by the European Group for the Immunological Classification of Leukemia (EGIL) scoring system and accounts for less than 5% of all acute Leukemia cases. Since it is a rare and heterogeneous form of acute Leukemia with an allegedly poor outcome, there is no consensus on the best treatment approach in these patients. Our objective was to analyze the biological features and outcome of patients diagnosed with BAL in our institution. PATIENTS AND METHODS Using the EGIL system, we identified 21 cases (3.9%) of BAL from 535 newly diagnosed acute Leukemia patients in an 11-year period. RESULTS There were ten cases of myeloid + B-lymphoid Leukemia, eight cases of myeloid + T-lymphoid, one case of B + T-lymphoid and two cases of trilineage (myeloid + B + T-lymphoid Leukemia). The complete remission (CR) rate with high-dose chemotherapy was 72% and overall survival at 5 years was 21%. Patients that received acute lymphoblastic Leukemia-oriented chemotherapy had a higher CR rate compared with those who received acute myeloid Leukemia-oriented chemotherapy (100% vs. 60%, P = .007). The white blood cell count at diagnosis was found to have statistically significant impact on survival. CONCLUSION Despite the progress in the treatment of acute Leukemia, the prognosis of BAL remains poor and treatment protocols devised explicitly for this entity should be investigated in prospective collaborative studies.

  • p015 outcome in a small series of biphenotypic acute Leukemia bal patients
    Leukemia Research, 2007
    Co-Authors: Mirta Mikulic, Drago Batinic, Klara Dubravcic, Damir Nemet, Ranka Serventiseiwerth, Dubravka Sertic, L Rnjak, Mirando Mrsic, Mirna Golemovic, Sanja Mrsic
    Abstract:

    Background: Less than 5% of all cases of acute Leukemia are classified as biphenotypic acute Leukemia (BAL). Being a distinct entity recognized by the WHO Classification, BAL is immunophenotypically defined by the European Group for the Immunological Classification of Leukemia (EGIL) scoring system, whereas according to FAB Classification BAL may present as one of the ALL or AML subtypes. Since BAL is both a rare form of acute Leukemia and shows diverse biological features, there is no consensus on the best treatment approach in these patients. Aim: Our aim was to analyze the laboratory characteristics and the outcome of patients diagnosed with BAL. Patients and methods: Using the EGIL system, we identified 21 cases (4%) of BAL from 535 newly diagnosed acute Leukemia patients in the Zagreb Clinical Hospital Center in the period from end 1994-2006. Results: There were 16 male and 5 female patients with median age of 44 years (16- 74). Among them, there were 12 cases of B+myeloid Leukemia (55%), 8 cases of T+myeloid (36%), 1 case of B+T lymphoid (5%) and 1 case of trilineage B+T+myeloid Leukemia (5%). Morphologic assessment showed myeloid features in 9, lymphoid features in 6 and undifferentiated in 6 patients. Cytogenetic findings revealed normal as well as a wide range of aberrant karyotypes. The patients were treated according to the protocols for AML or ALL or with low-dose chemotherapy - 8, 10 and 3 patients, respectively. In the majority of patients overall survival was poor with a median of 7 months (1- 100) and with a probability of survival at two years of 35%. Conclusion: Despite the progress in the treatment of acute Leukemia, the definition and the prognosis of BAL remains poor. Current treatment approach is heterogeneous and still based on cytomorphology. Treatment protocols designed specifically for this type of Leukemia should be devised and studied in larger groups of patients.

Dubravka Sertic - One of the best experts on this subject based on the ideXlab platform.

  • biological features and outcome of biphenotypic acute Leukemia a case series
    Hematology Oncology and Stem Cell Therapy, 2008
    Co-Authors: Mirta Mikulic, Drago Batinic, Mirna Sucic, Sanja Davidovicmrsic, Klara Dubravcic, Damir Nemet, Ranka Serventiseiwerth, Dubravka Sertic, Boris Labar
    Abstract:

    BACKGROUND Biphenotypic acute Leukemia (BAL) is a distinct entity that is immunophenotypically defined by the European Group for the Immunological Classification of Leukemia (EGIL) scoring system and accounts for less than 5% of all acute Leukemia cases. Since it is a rare and heterogeneous form of acute Leukemia with an allegedly poor outcome, there is no consensus on the best treatment approach in these patients. Our objective was to analyze the biological features and outcome of patients diagnosed with BAL in our institution. PATIENTS AND METHODS Using the EGIL system, we identified 21 cases (3.9%) of BAL from 535 newly diagnosed acute Leukemia patients in an 11-year period. RESULTS There were ten cases of myeloid + B-lymphoid Leukemia, eight cases of myeloid + T-lymphoid, one case of B + T-lymphoid and two cases of trilineage (myeloid + B + T-lymphoid Leukemia). The complete remission (CR) rate with high-dose chemotherapy was 72% and overall survival at 5 years was 21%. Patients that received acute lymphoblastic Leukemia-oriented chemotherapy had a higher CR rate compared with those who received acute myeloid Leukemia-oriented chemotherapy (100% vs. 60%, P = .007). The white blood cell count at diagnosis was found to have statistically significant impact on survival. CONCLUSION Despite the progress in the treatment of acute Leukemia, the prognosis of BAL remains poor and treatment protocols devised explicitly for this entity should be investigated in prospective collaborative studies.

  • p015 outcome in a small series of biphenotypic acute Leukemia bal patients
    Leukemia Research, 2007
    Co-Authors: Mirta Mikulic, Drago Batinic, Klara Dubravcic, Damir Nemet, Ranka Serventiseiwerth, Dubravka Sertic, L Rnjak, Mirando Mrsic, Mirna Golemovic, Sanja Mrsic
    Abstract:

    Background: Less than 5% of all cases of acute Leukemia are classified as biphenotypic acute Leukemia (BAL). Being a distinct entity recognized by the WHO Classification, BAL is immunophenotypically defined by the European Group for the Immunological Classification of Leukemia (EGIL) scoring system, whereas according to FAB Classification BAL may present as one of the ALL or AML subtypes. Since BAL is both a rare form of acute Leukemia and shows diverse biological features, there is no consensus on the best treatment approach in these patients. Aim: Our aim was to analyze the laboratory characteristics and the outcome of patients diagnosed with BAL. Patients and methods: Using the EGIL system, we identified 21 cases (4%) of BAL from 535 newly diagnosed acute Leukemia patients in the Zagreb Clinical Hospital Center in the period from end 1994-2006. Results: There were 16 male and 5 female patients with median age of 44 years (16- 74). Among them, there were 12 cases of B+myeloid Leukemia (55%), 8 cases of T+myeloid (36%), 1 case of B+T lymphoid (5%) and 1 case of trilineage B+T+myeloid Leukemia (5%). Morphologic assessment showed myeloid features in 9, lymphoid features in 6 and undifferentiated in 6 patients. Cytogenetic findings revealed normal as well as a wide range of aberrant karyotypes. The patients were treated according to the protocols for AML or ALL or with low-dose chemotherapy - 8, 10 and 3 patients, respectively. In the majority of patients overall survival was poor with a median of 7 months (1- 100) and with a probability of survival at two years of 35%. Conclusion: Despite the progress in the treatment of acute Leukemia, the definition and the prognosis of BAL remains poor. Current treatment approach is heterogeneous and still based on cytomorphology. Treatment protocols designed specifically for this type of Leukemia should be devised and studied in larger groups of patients.

Damir Nemet - One of the best experts on this subject based on the ideXlab platform.

  • biological features and outcome of biphenotypic acute Leukemia a case series
    Hematology Oncology and Stem Cell Therapy, 2008
    Co-Authors: Mirta Mikulic, Drago Batinic, Mirna Sucic, Sanja Davidovicmrsic, Klara Dubravcic, Damir Nemet, Ranka Serventiseiwerth, Dubravka Sertic, Boris Labar
    Abstract:

    BACKGROUND Biphenotypic acute Leukemia (BAL) is a distinct entity that is immunophenotypically defined by the European Group for the Immunological Classification of Leukemia (EGIL) scoring system and accounts for less than 5% of all acute Leukemia cases. Since it is a rare and heterogeneous form of acute Leukemia with an allegedly poor outcome, there is no consensus on the best treatment approach in these patients. Our objective was to analyze the biological features and outcome of patients diagnosed with BAL in our institution. PATIENTS AND METHODS Using the EGIL system, we identified 21 cases (3.9%) of BAL from 535 newly diagnosed acute Leukemia patients in an 11-year period. RESULTS There were ten cases of myeloid + B-lymphoid Leukemia, eight cases of myeloid + T-lymphoid, one case of B + T-lymphoid and two cases of trilineage (myeloid + B + T-lymphoid Leukemia). The complete remission (CR) rate with high-dose chemotherapy was 72% and overall survival at 5 years was 21%. Patients that received acute lymphoblastic Leukemia-oriented chemotherapy had a higher CR rate compared with those who received acute myeloid Leukemia-oriented chemotherapy (100% vs. 60%, P = .007). The white blood cell count at diagnosis was found to have statistically significant impact on survival. CONCLUSION Despite the progress in the treatment of acute Leukemia, the prognosis of BAL remains poor and treatment protocols devised explicitly for this entity should be investigated in prospective collaborative studies.

  • p015 outcome in a small series of biphenotypic acute Leukemia bal patients
    Leukemia Research, 2007
    Co-Authors: Mirta Mikulic, Drago Batinic, Klara Dubravcic, Damir Nemet, Ranka Serventiseiwerth, Dubravka Sertic, L Rnjak, Mirando Mrsic, Mirna Golemovic, Sanja Mrsic
    Abstract:

    Background: Less than 5% of all cases of acute Leukemia are classified as biphenotypic acute Leukemia (BAL). Being a distinct entity recognized by the WHO Classification, BAL is immunophenotypically defined by the European Group for the Immunological Classification of Leukemia (EGIL) scoring system, whereas according to FAB Classification BAL may present as one of the ALL or AML subtypes. Since BAL is both a rare form of acute Leukemia and shows diverse biological features, there is no consensus on the best treatment approach in these patients. Aim: Our aim was to analyze the laboratory characteristics and the outcome of patients diagnosed with BAL. Patients and methods: Using the EGIL system, we identified 21 cases (4%) of BAL from 535 newly diagnosed acute Leukemia patients in the Zagreb Clinical Hospital Center in the period from end 1994-2006. Results: There were 16 male and 5 female patients with median age of 44 years (16- 74). Among them, there were 12 cases of B+myeloid Leukemia (55%), 8 cases of T+myeloid (36%), 1 case of B+T lymphoid (5%) and 1 case of trilineage B+T+myeloid Leukemia (5%). Morphologic assessment showed myeloid features in 9, lymphoid features in 6 and undifferentiated in 6 patients. Cytogenetic findings revealed normal as well as a wide range of aberrant karyotypes. The patients were treated according to the protocols for AML or ALL or with low-dose chemotherapy - 8, 10 and 3 patients, respectively. In the majority of patients overall survival was poor with a median of 7 months (1- 100) and with a probability of survival at two years of 35%. Conclusion: Despite the progress in the treatment of acute Leukemia, the definition and the prognosis of BAL remains poor. Current treatment approach is heterogeneous and still based on cytomorphology. Treatment protocols designed specifically for this type of Leukemia should be devised and studied in larger groups of patients.